Related Experiment Video
Updated: Jun 25, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Discovery of the First-in-class G9a/GLP PROTAC Degrader
Julia Velez1, Yulin Han1, Hyerin Yim1
1Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Science, Oncological Science and Neuroscience, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Abstract:
Aberrantly expressed lysine methyltransferases G9a and GLP, which catalyze mono- and di-methylation of histone H3 lysine 9 (H3K9), have been implicated in numerous cancers. Recent studies have uncovered both catalytic and non-catalytic oncogenic functions of G9a/GLP. As such, G9a/GLP catalytic inhibitors have displayed limited anticancer activity. Here, we report the discovery of the first-in-class G9a/GLP proteolysis targeting chimera (PROTAC) degrader, 10 (MS8709), as a potential anticancer therapeutic. 10 induces G9a/GLP degradation in a concentration-, time, and ubiquitin-proteasome system (UPS)-dependent manner, does not alter the mRNA expression of G9a/GLP and is selective for G9a/GLP over other methyltransferases. Moreover, 10 displays superior cell growth inhibition to the parent G9a/GLP inhibitor UNC0642 in prostate, leukemia, and lung cancer cells and has suitable mouse pharmacokinetic properties for in vivo efficacy studies. Overall, 10 is a valuable chemical biology tool to further investigate the functions of G9a/GLP and a potential therapeutic for treating G9a/GLP-dependent cancers.
Insights
We developed a novel PROTAC degrader, compound 10 (MS8709), that effectively degrades G9a/GLP proteins. This new therapeutic shows promise for treating cancers dependent on G9a/GLP activity.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Aberrant expression of lysine methyltransferases G9a and GLP is linked to cancer development.
- G9a/GLP exhibit both catalytic and non-catalytic oncogenic functions.
- Existing G9a/GLP catalytic inhibitors show limited anticancer efficacy.
Conclusions:
- Compound 10 represents the first G9a/GLP PROTAC degrader with significant therapeutic potential.
- Compound 10 serves as a valuable chemical biology tool for studying G9a/GLP functions.
- Compound 10 holds promise for treating cancers driven by G9a/GLP activity.
Related Concept Videos
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
GPCR Desensitization

